Suchergebnisse - "Lau, Christie J"

PubPharm (8)

1

Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

enthalten in: Molecular cancer therapeutics | 2022

von Bahcall, M. | Paweletz, C. | Kuang, Y. | +15

2

Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade

enthalten in: The Journal of clinical investigation | 2021

von Sehgal, K. | Portell, A. | Ivanova, E. | +25

3

Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC

enthalten in: JCO precision oncology | 2021

von Cheng, M. | Lau, C. | Milan, M. | +6

4

Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health

enthalten in: JCO precision oncology | 2021

von Williams, P. | Forbes, T. | P Lund, S. | +14

5

Does Testing Error Underlie Liquid Biopsy Discordance?

enthalten in: JCO precision oncology | 2019

von Paweletz, C. | Lau, C. | Oxnard, G.

6

EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2019

von Rangachari, D. | To, C. | Shpilsky, J. | +8

7

Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade

enthalten in: Proceedings of the National Academy of Sciences of the United States of America | 2019

von Rashidian, M. | LaFleur, M. | Verschoor, V. | +13

8

Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer

enthalten in: Oral oncology | 2019

von Hanna, G. | Lau, C. | Mahmood, U. | +5

CommentIn: Oral Oncol. 2019 Oct;97:149-150. - PMID 31375418

1
[1]